• Recruiting

NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Updated: Jun 13


A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)


Cevostamab

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion using a modified weekly schedule.


Sponsor:

Genentech, Inc.


Collaborator:

Hoffmann-La Roche


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT04910568


Official Title: An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients With Relapsed or Refractory Multiple Myeloma


First Posted : June 2, 2021


Click here for details on ClinicalTrials.gov

 

Cevostamab


Cevostamab (Code C139549)

Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A

Anti-FCRH5/CD3 BiTE Antibody BFCR4350A

Anti-FCRH5/CD3 TDB BFCR4350A

BFCR4350A

Cevostamab

CEVOSTAMAB

FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A

FCRH5/CD3 TDB Antibody BFCR4350A

Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A

RO7187797

 

- California: City of Hope Duarte

- Missouri: Washington University School of Medicine Saint Louis

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

 

Locations

United States, California

United States, Colorado

United States, Michigan

United States, Missouri

Australia, Victoria

Canada, Ontario

Posts Archive